Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06194526
Other study ID # ACTC
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date September 19, 2023
Est. completion date September 2028

Study information

Verified date January 2024
Source MultiplAI Health Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The present clinical study aims to identify transcriptomic patterns derived from whole blood samples related to coronary atherotic burden. Additionally, as a secondary analysis, the research team will explore the algorithm's ability to detect the presence of aortic disease and pro-inflammatory cardiometabolic alterations, such as hepatic steatosis and surrogate markers of coronary inflammation.


Description:

This will be a prospective observational study. A convenience sample will be carried out to include 200 patients who attend the ENERI Medical Institute, La Sagrada Familia Clinic and Sanatorio Mendez with a clinical indication to be evaluated by a CCTA due to suspected CAD or known CAD. The study will have a baseline stage in which a clinical evaluation will be performed, blood samples will be drawn for transcriptome analysis and laboratory analysis. Then, a DNA sample obtained by swabbing the buccal mucose will be taken. Subsequently, the images obtained from the clinically indicated CCTA will be assessed to explore the outcomes of interest. At the end of patient enrollment, biological samples will be sequenced for in silico evaluation of the results. Finally, a 5-year follow-up will be carried out via telephone or email contact to collect data on the incidence of fatal and non-fatal cardiovascular events.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 200
Est. completion date September 2028
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Men and women between 18 and 75 years, with a clinical indication to be evaluated by a CCTA due to suspected or known CAD. - Signature of informed consent. Exclusion Criteria: - Previously known chronic renal or hepatic insufficiency. - Active chronic lung disease, defined as: exacerbated asthma, exacerbated COPD, or pulmonary fibrosis. - Myocardial infarction, unstable angina, cerebrovascular accident, or vascular interventions (any territory) in the past 6 months. - Implantation of drug-eluting stents in the last 12 months. - Revascularization surgery (By-pass) - Indication of Angio-CT for congenital heart disease or Transcatheter Aortic Valve Replacement (TAVI) - Presence/ diagnosis of heart failure symptoms or signs (ie. dyspnea, asthenia, edema) with objective evidence of pulmonary or systemic congestion at rest or with exercise in the last 6 months. - Left ventricular ejection fraction <50% confirmed by objective diagnostic methods (eg doppler echocardiogram). - Severe valvulopathies, confirmed by objective diagnostic methods (eg doppler echocardiogram). - Uncontrolled hyper or hypothyroidism. - Suprarenal insufficiency. - Previous surgeries in the last 3 months. - Severe trauma in the last 6 months, defined as one that involved bone fractures and/or surgical interventions. - Known active cancer disease or under treatment (acute or preventive), or history of cancer disease without criteria for cure. - Diagnosis of active autoimmune disease or any pathology under immunosuppressive treatment. - Ongoing pregnancy, postpartum period of less than 12 months or breastfeeding. - Other serious diseases with an estimated life expectancy of less than 12 months (according to the investigator's opinion). - Temperature greater than 37.5°C recorded by a thermometer or any acute infection caused by viruses or bacteria confirmed by a health professional in the previous 30 days. - Pacemaker/Cardio-Defibrillator Implantation. - Prior to the study: heart rate > 70 l/m or atrial fibrillation or frequent extrasystoles that in the opinion of the specialist physician will affect the quality of the cardiovascular imaging.

Study Design


Locations

Country Name City State
Argentina Clinica Sagrada Familia Ciudad Autónoma de Buenos Aire Ciudad Autónoma De Buenos Aires
Argentina Sanatorio Julio Mendez Ciudad Autónoma de Buenos Aire Ciudad Autónoma De Buenos Aires

Sponsors (2)

Lead Sponsor Collaborator
MultiplAI Health Limited Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary Coronary calcium score Coronary artery calcium (CAC) score (Agatston units) stratified with increasing risk according to the Society of Cardiovascular Computed Tomography Guidelines as CAC=0; CAC 1-99; CAC 100-299; and CAC=300. At baseline (cross-sectional assessment)
Primary Total coronary plaque burden The extension of atherosclerotic disease burden will be assessed using the Modified Duke prognostic CAD index as follows: 1) ,50% stenosis; (2) =2 non-obstructive stenoses (including one artery with proximal disease or one artery with 50-69% stenosis); (3) two vessels with stenoses 50-69% or one vessel with =70% stenosis; (4) three-vessel disease with stenoses 50-69%, or two vessels =70%, or proximal LAD stenosis =70%; (5) three-vessel disease with stenoses =70% or two-vessel disease =70% with proximal LAD; (6) left main stenosis =50%. At baseline (cross-sectional assesment)
Primary Degree of coronary stenosis Each coronary segment will be graded based on the degree of coronary stenosis as 0% (no visible stenosis), 1-24% (minimal stenosis); 25-49% (mild stenosis); 50-69% (moderate stenosis); 70-99% (severe stenosis); 100% (occluded). At baseline (cross-sectional assesment)
Primary Coronary high-risk plaques (low-attenuation, positive remodeling; spotty calcification, or napkin-ring sign) Presence of any of the following features: low-attenuation (average density equal or lower than 30 Hounsfield units), positive remodeling (remodeling index equal or higher than 1.1; spotty calcification (average density >130 HU, diameter <3 mm in any direction with the length of the calcium <1.5 times the vessel diameter and width of the calcification less than two-thirds of the vessel diameter), or napkin-ring sign (ring-like attenuation pattern with peripheral high attenuation tissue that surrounds a central lower attenuation portion). At baseline (cross-sectional assesment)
Secondary Presence and extent of aortic calcification Aortic valve calcification score (Agatston units) as a continuous variable with increasing risk and without preestablished thresholds (ranging from 0 to 5.000 Agatston units). At baseline (cross-sectional assessment)
Secondary Hepatic steatosis Defined as liver attenuation level lower than 48 Hounsfield units (HU), and lower than than the spleen attenuation. At baseline (cross-sectional assessment)
Secondary Coronary artery inflammation (perivascular fat attenuation index) This secondary analysis will be performed using using specific software. At baseline (cross-sectional assessment)
Secondary Death Death Up to 5 years of Follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT03427996 - Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice
Terminated NCT03175523 - HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging Versus Quantitative Coronary Angiography Guidance N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Completed NCT01184183 - Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy
Completed NCT00697372 - SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Phase 4
Completed NCT05509296 - Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease N/A
Recruiting NCT03054324 - Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis
Not yet recruiting NCT06039748 - Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
Not yet recruiting NCT05753085 - Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment N/A
Not yet recruiting NCT05471687 - Evaluation of the Functional Impact of Coronary Stenoses in Diabetics by Spectral CT N/A
Not yet recruiting NCT04569669 - The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis N/A
Active, not recruiting NCT02508714 - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents N/A
Completed NCT03301246 - Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart Disease N/A
Completed NCT03606330 - Systemic, Pancoronary and Local Coronary Vulnerability
Completed NCT02870140 - Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent N/A
Not yet recruiting NCT06071702 - IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System N/A
Completed NCT02275143 - Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis N/A
Active, not recruiting NCT01794065 - The Promus Element Rewards Study N/A
Completed NCT02120859 - Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty Phase 4